Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) recently announced the positive results from its Phase 3 clinical trial that evaluated SILENOR™ (doxepin HCl) in adults with transient insomnia.
The Phase III clinical data revealed that SILENOR™ demonstrated 
statistically significant improvements versus placebo (p<0.0001) in the primary endpoint of this trial, Latency to Persistent Sleep (LPS), a measure of sleep onset while in multiple secondary endpoints, produced statistically significant improvements relative to placebo, including measures of both sleep onset and sleep maintenance.
Over-all, study results demonstrated that 6mg of SILENOR™ was effective at inducing sleep and maintaining sleep throughout the night.
Find more details from Somaxon Pharmaceuticals, Inc.’s press release (a pdf file).
Comment Preview